MiNK Therapeutics (NASDAQ:INKT) Cut to Strong Sell at Wall Street Zen

Key Points

• MiNK Therapeutics (NASDAQ:INKT) has been downgraded to a "strong sell" rating by Wall Street Zen, following similar downgrades from other analysts.
• The company's stock has struggled recently, opening at $14.90, with a consensus rating of "Moderate Buy" and an average price target of $37.50.
• MiNK Therapeutics reported an EPS of ($1.06) for the latest quarter, missing analyst estimates of ($0.55) significantly, and is expected to post -2.75 EPS for the current year.

Wall Street Zen lowered shares of MiNK Therapeutics (NASDAQ:INKT - Free Report) to a strong sell rating in a research report report published on Saturday morning.

Other equities analysts also recently issued reports about the company. Zacks Research downgraded MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, August 18th. HC Wainwright raised shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective on the stock in a research note on Friday, August 15th. B. Riley raised MiNK Therapeutics to a "strong-buy" rating in a research note on Friday, July 18th. Finally, William Blair cut shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.50.

MiNK Therapeutics Stock Down 3.2%

Shares of MiNK Therapeutics stock traded down $0.51 during trading on Friday, reaching $15.48. The company's stock had a trading volume of 11,758 shares, compared to its average volume of 395,373. The business has a 50 day moving average price of $15.12 and a 200-day moving average price of $10.50. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $76.00. The company has a market capitalization of $69.95 million, a P/E ratio of -5.34 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.51). Research analysts predict that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.